Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 12.37 -0.37 (2.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.74 | 52 Week High | $30.40 | |||
| Open | $12.50 | 52 Week Low | $11.86 | |||
| Day High | $12.82 | P/E | N/A | |||
| Day Low | $12.23 | EPS | $0.00 | |||
| Volume | 1,560,282 | |||||
